Showing posts with label Environmental monitoring. Show all posts
Showing posts with label Environmental monitoring. Show all posts

Tuesday, 8 July 2025

Webinar: Getting Equipped for the Future with the New MAS-100 Sirius® Microbial Air Sampler

company banner 

The environment for pharmaceutical production has changed massively over the last few years. A clear trend towards digitalization and automation is observable. New regulatory requirements have been set for GMP-compliant aseptic manufacturing to minimize contamination risks in cleanrooms. In this webinar we will give an introduction to the portable new MAS-100 Sirius® Microbial Air Sampler, which meets the new challenges. We will demonstrate how it supports regulatory compliance in a digital environment, minimizes handling errors and makes active air monitoring easier to perform. Another key focus will be the validation process – highlighting what GAMP 5-based development is all about and how validation on customer side is supported.

Details: 

Thursday, July 10, 2025

9:00 AM Central European Summer Time

1 hour

To register see Air-sampling

In this webinar, you will learn:

  • How the MAS-100 Sirius® supports regulatory compliance in a digital environment.
  • Strategies to minimize handling errors and enhance active air monitoring
  • Insights into the validation process for effective implementation
To register

Speakers:

Corina Keller

Corina Keller

Product Manager, MBV AG

Corina Keller holds a master’s degree in biochemistry from the University of Zurich and an MBA from the Lucerne University of Applied Sciences and Arts. She has been working in product management for over seven years, focusing on translating customer needs into well-aligned product portfolio strategies. She is responsible for the portfolio of portable microbial air samplers and works closely with interdisciplinary teams to develop effective solutions for microbial air monitoring in pharmaceutical cleanrooms.

Dr. Anne-Grit Klees

Dr. Anne-Grit Klees

Global Product Manager, Merck KGaA, Darmstadt, Germany

Dr. Anne-Grit Klees is responsible for Innovation & Product Life Cycle Management with regard to microbial air samplers and media for aseptic process simulation for pharma cleanrooms and isolators. With a professional background in microbiology, she has been working in product and marketing management within the health industry for 30 years.

Register here. 

Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Wednesday, 30 April 2025

CGMP Requirements For Automated Facility Monitoring Systems


 

Monitoring systems (image by Tim Sandle)

In pharmaceuticals and healthcare, “facility” refers to the operational space, such as a cleanroom. The critical controls that maintain the facility are delivered through key utilities like air handling systems. To assess facility control, most organizations use facility monitoring systems (FMSs) to monitor the manufacturing workspaces continuously. Such systems are designed to be always on when the facility is in the operational state, ensuring compliance with important parameters across identified ranges. An important element for microbiological control is particle counting, which verifies the class of the cleanroom and indicates how well control is being maintained. Interconnected devices provide continuous monitoring of facilities, including aseptic and controlled environments. Other environmental data is also of importance for the contamination control strategy, including temperature, humidity, air velocity, and pressure. The design of these automated environmental monitoring systems should be based on quality risk management principles.

Sandle, T. (2023) CGMP Requirements For Automated Facility Monitoring Systems, Outsourced Pharma, August 2023: https://www.outsourcedpharma.com/doc/cgmp-requirements-for-automated-facility-monitoring-systems-0001

Also in:

BioProcess Online: https://www.bioprocessonline.com/doc/cgmp-requirements-for-automated-facility-monitoring-systems-0001
Pharmaceutical Online: https://www.pharmaceuticalonline.com/doc/cgmp-requirements-for-automated-facility-monitoring-systems-0001
Cell and Gene: https://www.cellandgene.com/doc/cgmp-requirements-for-automated-facility-monitoring-systems-0001
Biosimilar Development: https://www.biosimilardevelopment.com/doc/cgmp-requirements-for-automated-facility-monitoring-systems-0001
 

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Monday, 14 October 2024

Improving aseptic transfer: Advantages of the IsoBag® solution

IsoBag® (Merck image, with permission)
 

The revision to EU GMP Annex 1, in August 2022, updated the requirement for Grade A environments used during sterile manufacturing. This was the change in acceptance criteria to ‘no growth’ (from the previous value of 1 CFU). This change not only paves the way for alternative microbiological methods it signalled the shift in regulatory thinking towards the detection of any contamination within the aseptic core being atypical and problematic.



One of the dilemmas faced by microbiologists, on the recovery of contamination at Grade A, is whether the contamination derived from the aseptic operation or from the activity of transfer in to or out of the aseptic environment. If adventitious contamination cannot be verified, the recovery could lead to a batch rejection.



A potential microbial contamination transfer risk exists with both RABS (restricted access barrier systems) and isolators, given the need to introduce materials from outside of the protective barrier. While isolators afford greater protection by virtue of providing a complete barrier and an environment that can be subjected to an automated decontamination cycle, the transfer issue still presents a concern.



This article looks at the problem of transferring materials to the aseptic core from lower controlled environments and describes a solution from Merck that significantly improves the environmental monitoring workflow through the use of the IsoBag® solution.




Contamination transfer risks




One of the primary routes by which contamination enters the aseptic core is through material transfer, either on items or from personnel interacting with the transferred materials. Sources of microbial contamination represent hazards, and the level of risk depends on the likelihood of contamination being transferred from the source to the critical area. Assessing such risks and designing them out of the process is a central part of the Contamination Control Strategy (CCS). The CCS is an important component of Annex 1 (1).



This requires hazard analysis and risk assessment, as represented by figure 1:



 


Figure 1: Hazard analysis and assessment




With figure 1, risk is lowered through controls. Examples of controls required to reduce the risks include (1, 2):


  • Assessment of the vendor’s suitability to supply consumables.
  • Elimination of items unsuitable for introduction into a cleanroom. Need for incoming consumables to be multi-wrapped (minimum of three layers in addition to outer packaging).
  • Need for sporicidal disinfection when transferring between areas of different cleanliness levels (such as cleanrooms of different grades). 
  • The avoidance of items that generate fibres.
  • Using airlocks and transfer hatches between cleanrooms of different grades.
  • Having appropriate pressure differentials.
  • Ensuring airlocks and transfer hatches areas are interlocked and that alarms must be in place. Controlling the time of transfer so that disinfected items are subjected to the required contact time. 
  • For transfer between Grade C and B, in ensuring that items are flushed with HEPA filtered air.
  • Adopting ‘no touch’ solutions to transfer items into Grade A.




With each step, contamination can be transferred and any weakness leading to contamination being detected in the aseptic core may have arisen from the external packaging if decontamination steps were inadequate or if the execution of controls was performed inadequately. The CCS helps to drive consideration of the ‘bigger picture’.



Importantly the emphasis should always be on control. Achieving control is achieved by identifying hazards and then risk assessing these hazards for their severity (should they occur) and their likelihood of occurring. One aspect of control is with design improvement and the IsoBag® solution is an example of such an improvement.




IsoBag® solution




The IsoBag® solution enables bagged culture media and exposed plates to be successfully transferred into and out of an isolator, eliminating the opportunity for cross-contamination from personnel or from the environment. This transfer mechanism means that, post-incubation, any contamination detected is reflective of the Grade A environment.



Improving asepsis




Where plates are pre-loaded into an isolator ahead of decontamination, the process of packs of plates reaching the isolator requires a layer to be removed as the plates move from a preparation area to the surrounding isolator environment (typically EU GMP Grade C) and then into the isolator. This means that the plates presented to the isolator are only single wrapped. Whilst steps will be taken by personnel to minimise contamination transfer from the unwrapping process as plates transition through the facility this is a manual disinfection process. A reliance on manual disinfection will occasionally lead to contamination, given the intricacies of manual disinfection. Furthermore, no isolator decontamination process is 100% efficient, especially when endospore forming bacteria are transferred into the isolator and where there is the potential for occluded surfaces.



Reducing transfer risks




The design of the IsoBag® solution avoids contamination transfer through the use of an alpha-beta port system (where the alpha port is the port designed within the isolator and the beta port is the basis of the IsoBag®). The alpha-beta design is based on DPTE® technology.



DPTE® is a rapid transfer port technology, developed by Getinge, enabling a reliable and leak tight transfer. With the process, the alpha part and the beta part are connected by a manual 60° rotation which detaches the doors from their supports and then joins them together. Once these are secured, the doors can now be opened without breaking sterility or containment and items transferred.



Tightness is secured by the lip seals of the new assembly.



Enhancing sterility




IsoBag® are prepared prepacked with environmental monitoring plates. These plates, together with the complete bag assembly, are sterilised by radiation, which is a proven method of decontamination and effective against endospore forming bacteria.. The irradiation process is also demonstrated not to affect the growth promoting properties of the culture medium (with or without the addition of a disinfectant neutraliser).



Improving decontamination cycle robustness




Another advantage of the IsoBag® is that microbiological culture media, in the form of contact and settle plates, does not need to be placed inside the isolator to be decontaminated before use. When decontamination cycles are run, using methods like vapour hydrogen peroxide, the decontamination process is achieved through surface contact. The more items that are pre-loaded into the isolator then the greater the chance of insufficient surface contact occurring, or with surface occlusion arising, and hence inadequate decontamination.



The IsoBag® eliminates this step, thereby reducing the number of items that need to be placed inside the isolator in advance of decontamination and enabling culture media to be used as required.



Flexibility and space




The IsoBag® concept also increases the available space within the isolator and avoids it from becoming cluttered with too many plates. The IsoBag® enables only those plates that are required to be seamlessly transferred in. This creates more working space.



The concept also adds flexibility in that should more environmental monitoring media than was originally anticipated be needed, then additional plates can be rapidly transferred. The alpha-beta port system enables up to 10 connections and disconnections



in the process and keeping those plates available for use at any time. Unlike traditional methods, where single-bagged plates are decontaminated and stored in the isolator, limiting space and often interrupting workflow, with our IsoBag®, plates are mounted to the isolator’s port and used directly since they are already gamma-irradiated (ready-to-use). In addition to safety and efficiency, the process also frees up time and saves money.




Meeting data integrity expectations




The culture media transported via the IsoBag® is presented in a format that reduces cross-contamination through the plates having lockable lids, thereby ensuring that post-sampling contamination is unlikely. Data integrity is further enhanced through the use of 2D-datamatrix codes, which ensure sample traceability.



Summary




The activity of transferring materials in and out of the aseptic core requires planning and a highly-developed workflow. This is necessary to avoid introducing microorganisms into the critical area and for protecting samples from adventitious contamination after sampling. Failure to do so is problematic – either putting sterile products at risk or creating false negatives. The IsoBag® concept provides a mechanism to avoid these problems – both for transfer in and out of the isolator.



References




1. Sandle, T. (2023) Biocontamination Control for Pharmaceuticals and Healthcare, 2nd edition, Academic Press, London, UK

2. Strategy/Program: From Global Development to Site Implementation, American Pharmaceutical Review, at: https://www.americanpharmaceuticalreview.com/Featured-Articles/564173-Establishing-a-Contamination-Control-Strategy-Program-From-Global-Development-to-Site-Implementation/

 

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Tuesday, 2 July 2024

Means, ranges and replicates: Improving microbial plate counting


 

A microbial colony is a visible cluster of microorganisms growing on the surface of or within a solid medium. This may be from a single cell or an amalgam of the same organism of one than one cell or a mix of different organisms. Bioburden levels are commonly measured, when conventional methods are deployed, in terms of colony-forming units (CFUs). These units provide an estimation of the number of viable bacteria or fungal cells found on a sample, expressed against a unit of measurement (such as per milliliter or per milligram).

When counting CFUs on solid microbiological culture media (agar) there are some aspects of ‘counting’ that need to be considered. These are:

a) Rounding and averaging

b) Significant figures

c) Countable range

d) Statistical error from low counts

This week’s article looks at each of these aspects of the microbial plate count. 

See:  https://www.linkedin.com/pulse/means-ranges-replicates-improving-microbial-plate-tim-kbxke/

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Thursday, 19 October 2023

Review of alert and action level setting for microbiological cleanroom data


 

Scientific data is concerned with measuring and hence data, whether that is qualitative or quantitative. In pharmaceutical microbiology, this could be a number of cells or colony forming units, a series of growth or no growth results; and incidences of microorganisms. Gathering such data allows for trending and enables control to be achieved.

 

With microbial numbers, it is a regulatory expectation that alert and action levels be set. Alert and action levels are not specifications - they are ‘snap-shot’ indicators of potential adverse or upward trends, or out-of-control situations. Alert and action levels are used to detect shifts from the norm and to indicate if an individual result or process is potentially out-of-control. Therefore, what is important is the data pattern.

 

The standard approach is to set alert and action levels based on a set of historical data. Understanding past data enables for a more accurate assessment of current data in relation to the performance of a sample, system or environment. Furthermore, the use of this information ensures that the levels applied relate in some form to past data rather than being based on an arbitrary figure. Setting alert and action levels is hampered by data sets being distributed unusually, with the data containing many zeros (and so skewed to the left when a histogram is produced). This type of quality attribute is typically called a zero-inflated variable. Furthermore, there will often be occasional high values leading to a relatively high dispersal. The data is not always predictable and will contain a relatively high level of variability. One way to overcome this is through the use of the percentile cut-off approach.

 

Sandle, T. (2023) Review of alert and action level setting for microbiological cleanroom data, RSSL Life Science Insights, at: https://www.rssl.com/insights/life-science-pharmaceuticals/review-of-alert-and-action-level-setting-for-microbiological-cleanroom-data/

 

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Special offers